Subclinical vascular disease and cerebral glutamate elevation in metabolic syndrome

Andreana P. Haley, Mitzi M. Gonzales, Takashi Tarumi, Hirofumi Tanaka

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Metabolic syndrome (MetS), the co-occurrence of obesity, hypertension, hyperglycemia and dyslipidema, is an important risk factor for diabetes, cardiovascular disease and end-organ damage in the brain. Our goal was to determine if metabolic syndrome (MetS) differentially affects cerebral metabolism in middle-aged adults with varying degrees of subclinical vascular disease. Sixty-five neurologically healthy adults aged 40 to 60 years (19 with MetS and 46 controls) underwent ultrasound examination of carotid artery intima-media thickness (IMT), a measure of peripheral vascular disease, a full neuropsychological evaluation, and a proton magnetic resonance spectroscopy (1H MRS) scan of occipitoparietal grey matter. The Johnson- Neyman technique and pick-a-point approach were used to test if MetS-related neurochemical changes were moderated by IMT. The MetS and control groups were comparable in age, education, gender distribution, average IMT, and cognitive performance. MetS individuals with low IMT values (1 SD below sample mean) demonstrated comparable neurochemical concentrations to the healthy controls (t=-0.21, p00.84, 95 % CI -0.106 to 0.086), while MetS individuals with high IMT values (1 SD above sample mean) exhibited significantly elevated glutamate concentrations (t=2.84, p00.006, 95 % CI 0.038 to 0.220). We found that the level of peripheral atherosclerosis moderated the level of elevation of cerebral glutamate concentrations in patients with MetS. These results suggest that peripheral metabolic dysfunction in midlife likely acts in conjunction with subclinical vascular disease to foster pro-neurotoxic conditions in the central nervous system creating early brain vulnerability.

Original languageEnglish (US)
Pages (from-to)513-520
Number of pages8
JournalMetabolic Brain Disease
Volume27
Issue number4
DOIs
StatePublished - Dec 1 2012

Fingerprint

Vascular Diseases
Glutamic Acid
Brain
Magnetic resonance spectroscopy
Neurology
Medical problems
Metabolism
Education
Ultrasonics
Nuclear magnetic resonance
Carotid Intima-Media Thickness
Peripheral Vascular Diseases
Carotid Arteries
Hyperglycemia
Atherosclerosis
Cardiovascular Diseases
Central Nervous System
Obesity
Hypertension
Control Groups

Keywords

  • Atherosclerosis
  • Brain imaging
  • Carotid ultrasound
  • Glutamate
  • Metabolic syndrome
  • MR spectroscopy

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

Subclinical vascular disease and cerebral glutamate elevation in metabolic syndrome. / Haley, Andreana P.; Gonzales, Mitzi M.; Tarumi, Takashi; Tanaka, Hirofumi.

In: Metabolic Brain Disease, Vol. 27, No. 4, 01.12.2012, p. 513-520.

Research output: Contribution to journalArticle

Haley, Andreana P. ; Gonzales, Mitzi M. ; Tarumi, Takashi ; Tanaka, Hirofumi. / Subclinical vascular disease and cerebral glutamate elevation in metabolic syndrome. In: Metabolic Brain Disease. 2012 ; Vol. 27, No. 4. pp. 513-520.
@article{67d1e8b9563f4b489ffb49a717180b41,
title = "Subclinical vascular disease and cerebral glutamate elevation in metabolic syndrome",
abstract = "Metabolic syndrome (MetS), the co-occurrence of obesity, hypertension, hyperglycemia and dyslipidema, is an important risk factor for diabetes, cardiovascular disease and end-organ damage in the brain. Our goal was to determine if metabolic syndrome (MetS) differentially affects cerebral metabolism in middle-aged adults with varying degrees of subclinical vascular disease. Sixty-five neurologically healthy adults aged 40 to 60 years (19 with MetS and 46 controls) underwent ultrasound examination of carotid artery intima-media thickness (IMT), a measure of peripheral vascular disease, a full neuropsychological evaluation, and a proton magnetic resonance spectroscopy (1H MRS) scan of occipitoparietal grey matter. The Johnson- Neyman technique and pick-a-point approach were used to test if MetS-related neurochemical changes were moderated by IMT. The MetS and control groups were comparable in age, education, gender distribution, average IMT, and cognitive performance. MetS individuals with low IMT values (1 SD below sample mean) demonstrated comparable neurochemical concentrations to the healthy controls (t=-0.21, p00.84, 95 {\%} CI -0.106 to 0.086), while MetS individuals with high IMT values (1 SD above sample mean) exhibited significantly elevated glutamate concentrations (t=2.84, p00.006, 95 {\%} CI 0.038 to 0.220). We found that the level of peripheral atherosclerosis moderated the level of elevation of cerebral glutamate concentrations in patients with MetS. These results suggest that peripheral metabolic dysfunction in midlife likely acts in conjunction with subclinical vascular disease to foster pro-neurotoxic conditions in the central nervous system creating early brain vulnerability.",
keywords = "Atherosclerosis, Brain imaging, Carotid ultrasound, Glutamate, Metabolic syndrome, MR spectroscopy",
author = "Haley, {Andreana P.} and Gonzales, {Mitzi M.} and Takashi Tarumi and Hirofumi Tanaka",
year = "2012",
month = "12",
day = "1",
doi = "10.1007/s11011-012-9306-x",
language = "English (US)",
volume = "27",
pages = "513--520",
journal = "Metabolic Brain Disease",
issn = "0885-7490",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Subclinical vascular disease and cerebral glutamate elevation in metabolic syndrome

AU - Haley, Andreana P.

AU - Gonzales, Mitzi M.

AU - Tarumi, Takashi

AU - Tanaka, Hirofumi

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Metabolic syndrome (MetS), the co-occurrence of obesity, hypertension, hyperglycemia and dyslipidema, is an important risk factor for diabetes, cardiovascular disease and end-organ damage in the brain. Our goal was to determine if metabolic syndrome (MetS) differentially affects cerebral metabolism in middle-aged adults with varying degrees of subclinical vascular disease. Sixty-five neurologically healthy adults aged 40 to 60 years (19 with MetS and 46 controls) underwent ultrasound examination of carotid artery intima-media thickness (IMT), a measure of peripheral vascular disease, a full neuropsychological evaluation, and a proton magnetic resonance spectroscopy (1H MRS) scan of occipitoparietal grey matter. The Johnson- Neyman technique and pick-a-point approach were used to test if MetS-related neurochemical changes were moderated by IMT. The MetS and control groups were comparable in age, education, gender distribution, average IMT, and cognitive performance. MetS individuals with low IMT values (1 SD below sample mean) demonstrated comparable neurochemical concentrations to the healthy controls (t=-0.21, p00.84, 95 % CI -0.106 to 0.086), while MetS individuals with high IMT values (1 SD above sample mean) exhibited significantly elevated glutamate concentrations (t=2.84, p00.006, 95 % CI 0.038 to 0.220). We found that the level of peripheral atherosclerosis moderated the level of elevation of cerebral glutamate concentrations in patients with MetS. These results suggest that peripheral metabolic dysfunction in midlife likely acts in conjunction with subclinical vascular disease to foster pro-neurotoxic conditions in the central nervous system creating early brain vulnerability.

AB - Metabolic syndrome (MetS), the co-occurrence of obesity, hypertension, hyperglycemia and dyslipidema, is an important risk factor for diabetes, cardiovascular disease and end-organ damage in the brain. Our goal was to determine if metabolic syndrome (MetS) differentially affects cerebral metabolism in middle-aged adults with varying degrees of subclinical vascular disease. Sixty-five neurologically healthy adults aged 40 to 60 years (19 with MetS and 46 controls) underwent ultrasound examination of carotid artery intima-media thickness (IMT), a measure of peripheral vascular disease, a full neuropsychological evaluation, and a proton magnetic resonance spectroscopy (1H MRS) scan of occipitoparietal grey matter. The Johnson- Neyman technique and pick-a-point approach were used to test if MetS-related neurochemical changes were moderated by IMT. The MetS and control groups were comparable in age, education, gender distribution, average IMT, and cognitive performance. MetS individuals with low IMT values (1 SD below sample mean) demonstrated comparable neurochemical concentrations to the healthy controls (t=-0.21, p00.84, 95 % CI -0.106 to 0.086), while MetS individuals with high IMT values (1 SD above sample mean) exhibited significantly elevated glutamate concentrations (t=2.84, p00.006, 95 % CI 0.038 to 0.220). We found that the level of peripheral atherosclerosis moderated the level of elevation of cerebral glutamate concentrations in patients with MetS. These results suggest that peripheral metabolic dysfunction in midlife likely acts in conjunction with subclinical vascular disease to foster pro-neurotoxic conditions in the central nervous system creating early brain vulnerability.

KW - Atherosclerosis

KW - Brain imaging

KW - Carotid ultrasound

KW - Glutamate

KW - Metabolic syndrome

KW - MR spectroscopy

UR - http://www.scopus.com/inward/record.url?scp=84871432789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871432789&partnerID=8YFLogxK

U2 - 10.1007/s11011-012-9306-x

DO - 10.1007/s11011-012-9306-x

M3 - Article

VL - 27

SP - 513

EP - 520

JO - Metabolic Brain Disease

JF - Metabolic Brain Disease

SN - 0885-7490

IS - 4

ER -